Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis.

MLA

Taha-Mehlitz, Stephanie, et al. “Adenylosuccinate Lyase Is Oncogenic in Colorectal Cancer by Causing Mitochondrial Dysfunction and Independent Activation of NRF2 and MTOR-MYC-Axis.” Theranostics, vol. 11, no. 9, Feb. 2021, pp. 4011–29. EBSCOhost, https://doi.org/10.7150/thno.50051.

APA

Taha-Mehlitz, S., Bianco, G., Coto-Llerena, M., Kancherla, V., Bantug, G. R., Gallon, J., Ercan, C., Panebianco, F., Eppenberger-Castori, S., von Strauss, M., Staubli, S., Bolli, M., Peterli, R., Matter, M. S., Terracciano, L. M., von Flüe, M., Ng, C. K. Y., Soysal, S. D., Kollmar, O., & Piscuoglio, S. (2021). Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis. Theranostics, 11(9), 4011–4029. https://doi.org/10.7150/thno.50051

Chicago

Taha-Mehlitz, Stephanie, Gaia Bianco, Mairene Coto-Llerena, Venkatesh Kancherla, Glenn R Bantug, John Gallon, Caner Ercan, et al. 2021. “Adenylosuccinate Lyase Is Oncogenic in Colorectal Cancer by Causing Mitochondrial Dysfunction and Independent Activation of NRF2 and MTOR-MYC-Axis.” Theranostics 11 (9): 4011–29. doi:10.7150/thno.50051.